Mr. Ali Hedayat reports

DRI HEALTHCARE COMMENTS ON FDA APPROVAL AND OUR INCREASED INVESTMENT IN KALVISTA PHARMACEUTICALS' EKTERLY (SEBETRALSTAT)

DRI Healthcare Trust has noted KalVista Pharmaceuticals has received approval from the U.S. Food and Drug Administration for Ekterly (sebetralstat). Ekterly is approved for the treatment of acute attacks of hereditary angioedema in adult and pediatric patients aged 12 years and older. HAE is a rare genetic disorder characterized by recurring episodes of severe swelling in various parts of the body, including the face, extremities, gastrointestinal tract and airways.

"We are very pleased that the FDA has approved Ekterly as the first and only oral on-demand therapy for treating HAE attacks," said Ali Hedayat, chief executive officer of DRI Healthcare. "The addition of the long-dated Ekterly cash flows demonstrates the value that a preapproval transaction can bring to our portfolio."

"We congratulate our partners at KalVista, who worked diligently to develop Ekterly to help transform the lives of patients who suffer from HAE," added Navin Jacob, executive vice-president and chief investment officer.

KalVista has notified DRI Healthcare that it has elected to receive the optional payment of $22-million as part of the November, 2024, royalty transaction. As a result of receiving this one-time payment, the royalty rate on the first sales tranche steps up, and the sales-based milestone amount increases. The transaction now entitles DRI Healthcare to a tiered royalty of 6.00 per cent on net sales up to and including $500-million, 1.10 per cent on net sales above $500-million and up to and including $750-million, and 0.25 per cent on net sales above $750-million. KalVista is entitled to a potential one-time sales-based milestone payment of $57-million if annual worldwide net sales of sebetralstat meet or exceed $550-million in any calendar year before Jan. 1, 2031.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, it has deployed more than $3.0-billion, acquiring more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.